{
    "clinical_study": {
        "@rank": "48566", 
        "acronym": "C4C", 
        "arm_group": [
            {
                "arm_group_label": "Flucloxacillin and placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intravenous or oral Flucloxacillin with an oral placebo"
            }, 
            {
                "arm_group_label": "Flucloxacillin and Clindamycin", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravenous or oral Flucloxacillin with oral Clindamycin"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to see whether the addition of Clindamycin, a protein inhibiting\n      antibiotic, to the standard antibiotic treatment of limb cellulitis, with Flucloxacillin,\n      results in less tissue damage and a more rapid resolution of both systemic and local\n      features, in a cost-effective manner. This study is a randomised controlled trial comparing\n      Clindamycin with placebo."
        }, 
        "brief_title": "Adjunctive Clindamycin for Cellulitis: Clinical Trial Comparing Flucloxacillin With or Without Clindamycin for the Treatment of Limb Cellulitis (C4C Trial).", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cellulitis", 
        "condition_browse": {
            "mesh_term": "Cellulitis"
        }, 
        "detailed_description": {
            "textblock": "Criteria to be used to assess tissue damage and clinical response:\n\n        1. Fever, tachycardia, neutrophil count, urea and other laboratory parameters at five and\n           ten days post first dose of clindamycin\n\n        2. Limb swelling (by the measurement of limb circumference), skin surface temperature and\n           tissue damage (by the proportion of the limb affected)\n\n        3. Document the duration between initial systemic features and the development of local\n           signs\n\n        4. Examine the effect of the duration between systemic and local features and first dose\n           of flucloxacillin on the subsequent duration and severity of cellulitis\n\n        5. Examine the effect of duration between the first dose of flucloxacillin and the first\n           dose of clindamycin on the subsequent duration and severity of cellulitis\n\n        6. Identify and quantify possible side effects of clindamycin"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects aged 18 or over who have a diagnosis of cellulitis of a\n             single, upper or lower, limb\n\n          -  Who are able to understand the study and give consent\n\n          -  Who are able to take oral medication\n\n        Exclusion Criteria:\n\n          -  Patients with a confirmed history of penicillin, flucloxacillin or clindamycin\n             allergy\n\n          -  Patients known to be colonised with Methicillin-resistant Staphylococcus aureus or\n             Methicillin-resistant Staphylococcus aureus isolated from wound within the last year\n\n          -  Patients unable to take oral medication\n\n          -  Previous history of Clostridium difficile colitis\n\n          -  Clindamycin taken within the last 30 days\n\n          -  Clinically unstable\n\n          -  Unable to understand the study or give consent\n\n          -  Any doubt over the certainty of the diagnosis of cellulitis\n\n          -  Patients taking any drug that is incompatible with either flucloxacillin or\n             clindamycin\n\n          -  Pre-existing diarrhoea"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01876628", 
            "org_study_id": "C4C-4078", 
            "secondary_id": "2013-001218-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "Flucloxacillin and Clindamycin", 
                "description": "Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.", 
                "intervention_name": "Flucloxacillin and Clindamycin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Floxapen", 
                    "Fluclomix", 
                    "Ladropen", 
                    "Dalacin C", 
                    "Lincocin", 
                    "Daclin"
                ]
            }, 
            {
                "arm_group_label": "Flucloxacillin and placebo", 
                "description": "Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days", 
                "intervention_name": "Flucloxacillin and placebo", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Floxapen", 
                    "Fluclomix", 
                    "Ladropen"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clindamycin", 
                "Clindamycin-2-phosphate", 
                "Floxacillin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Clindamycin", 
            "Cellulitis", 
            "Flucloxacillin", 
            "Group A streptococcus", 
            "Staphylococcus aureus"
        ], 
        "lastchanged_date": "October 30, 2013", 
        "location": {
            "contact": {
                "email": "bristol.cellulitis@uhbristol.nhs.uk", 
                "last_name": "Richard Brindle, DM"
            }, 
            "contact_backup": {
                "email": "bristol.cellulitis@uhbristol.nhs.uk", 
                "last_name": "Martin O Williams, PhD, MB BCh"
            }, 
            "facility": {
                "address": {
                    "city": "Bristol", 
                    "country": "United Kingdom", 
                    "zip": "BS2 8HW"
                }, 
                "name": "University Hospitals Bristol NHS Foundation Trust"
            }, 
            "investigator": {
                "last_name": "Richard Brindle, DM", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double Blind Randomised Control Trial to Measure the Effect of the Addition of Clindamycin to Flucloxacillin for the Treatment of Limb Cellulitis", 
        "overall_contact": {
            "email": "richard.brindle@uhbristol.nhs.uk", 
            "last_name": "Richard Brindle, DM", 
            "phone": "+441173423365"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: National Institute for Health Research", 
                "United Kingdom: National Health Service", 
                "United Kingdom: Department of Health", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Temperature less than 37.5 degrees centigrade, and a reduction in limb swelling", 
            "measure": "Improvement based on a composite of systemic and local features", 
            "safety_issue": "No", 
            "time_frame": "Day 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01876628"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessed using a visual analogue score", 
                "measure": "Decrease in pain", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }, 
            {
                "description": "Assessment based on a questionnaire plus return to work or normal activities and absence of increased side-effects.", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "Day 30"
            }, 
            {
                "description": "Resolution of systemic features, composite inflammatory markers and recovery of renal function.", 
                "measure": "Physiological recovery", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }
        ], 
        "source": "University Hospitals Bristol NHS Trust", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Bristol", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Health Protection Agency, United Kingdom", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University Hospitals Bristol NHS Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}